Radiotherapy After Surgery Cut Brain Tumor Recurrence
Patients with atypical meningiomas may reduce their risk of tumor return by receiving targeted radiation after surgery.
Updated on Sept. 25, 2026 in Cancer
Live Poll
Would you follow new study findings to guide your personal medical treatment decisions?
A study published in The Lancet found that radiotherapy following surgery significantly reduced brain cancer recurrence rates compared to monitoring alone. This finding may alter the standard of care for patients with atypical meningiomas.
Why it matters
Atypical meningiomas have a high tendency to return within five years of surgical removal, necessitating more effective preventive strategies. This research provides evidence that adjuvant therapy could improve long-term disease-free survival for this patient population.
In a randomized trial of 157 patients, those who received six weeks of daily radiotherapy after surgery had an 80% five-year disease-free survival rate, compared to 64% in the observation group. These findings remain preliminary pending further long-term follow-up.
The players
The Lancet
A prestigious weekly peer-reviewed general medical journal that publishes major clinical research findings.
Andy Tudor
A patient who underwent stereotactic radiotherapy for a recurring atypical meningioma.
The details
Researchers evaluated how targeted radiotherapy, administered daily over six weeks, acts to prevent the regrowth of residual atypical meningioma cells left behind after surgery. While the therapy was effective at reducing tumor recurrence, patients in the study reported common short-term side effects including hair loss and headache. This approach contrasts with active monitoring, which delays intervention until a recurrence is detected on follow-up imaging.
Timeline
2016-2021: Patients were enrolled in the medical trial.
2017: Andy Tudor was diagnosed with atypical meningioma.
January 2022: Andy Tudor experienced a tumor recurrence.
March 2022: Andy Tudor received stereotactic radiotherapy.
Health Landscape
This study contributes to the clinical research conducted by the University of Liverpool regarding the optimal management of atypical meningiomas. It represents a significant step in determining whether adjuvant radiation should become the new standard of care for these specific tumors.
Patients diagnosed with atypical meningioma may want to discuss the potential benefits and side effects of post-surgical radiotherapy with their neuro-oncologist. It is worth asking how these findings might apply to your specific tumor characteristics and overall treatment plan.
The takeaway
Radiotherapy shows promise in preventing the return of atypical meningiomas following surgical removal. If you or a loved one are navigating a brain tumor diagnosis, talk to your medical team about current evidence for adjuvant therapies and appropriate monitoring schedules.
Further reading
For more on evolving treatment options and the latest clinical research, visit Cancer.
Live Poll
Would you follow new study findings to guide your personal medical treatment decisions?
